Should You Buy MannKind Corp (MNKD) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
MannKind Corp (MNKD) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite positive catalysts like FDA decisions and a growing revenue trend, the stock's recent technical indicators, weak financial performance in net income and EPS, and hedge fund selling suggest caution. Holding the stock or waiting for a better entry point is advised.
Technical Analysis
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 41.921, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 5.175), but the overall trend is bearish with a regular market change of -7.61%.
Analyst Ratings and Price Target Trends
Analysts are optimistic about MannKind's long-term growth, with Buy ratings and price targets between $9 and $11. However, Oppenheimer recently lowered its price target from $15 to $10 due to the discontinuation of a Phase 3 trial, reflecting some concerns about the pipeline.
Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.25 USD with a low forecast of 7.5 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.25 USD with a low forecast of 7.5 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 5.640
Current: 5.640
